Three years evaluation of peritoneal dialysis and hemodialysis absorption costing: perspective of the service provider compared to funds transfers from the public and private healthcare systems

被引:0
|
作者
Schreider, Alyne [1 ]
de Moraes Junior, Celso Souza [2 ]
da Silva Fernandes, Natalia Maria [1 ]
机构
[1] Univ Fed Juiz de Fora, Fac Med, Inst Ciencias Biol, Juiz De Fora, MG, Brazil
[2] Univ Fed Juiz de Fora, Fac Adm & Ciencias Contabeis, Juiz De Fora, MG, Brazil
来源
JORNAL BRASILEIRO DE NEFROLOGIA | 2022年 / 44卷 / 02期
关键词
Costs and Cost Analysis; Health Expenditures; Unified Health System; Supplemental Health; Peritoneal Dialysis; Renal Dialysis; RENAL REPLACEMENT THERAPIES; DISEASE; BRAZIL;
D O I
10.1590/2175-8239-JBN-2021-0118
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: 72% of renal replacement therapy (RRT) clinics in Brazil are private. However, regarding payment for dialysis therapy, 80% of the patients are covered by the Unified Health System (SUS) and 20% by private healthcare (PH). Objectives: To evaluate costs for peritoneal dialysis (PD) and hemodialysis (HD) from the perspective of the service provider and compare with fund transfers from SUS and private healthcare. Methods: The absorption costing method was applied in a private clinic. Study horizon: January 2013 - December 2016. Analyzed variables: personnel, medical supplies, tax expenses, permanent assets, and labor benefits. The input-output matrix method was used for analysis. Results: A total of 27,666 HD sessions were performed in 2013, 26,601 in 2014, 27,829 in 2015, and 28,525 in 2016. There were 264 patients on PD in 2013, 348 in 2014, 372 in 2015, and 300 in 2016. The mean monthly cost of the service provider was R$ 981.10 for a HD session for patients with hepatitis B; R$ 238.30 for hepatitis C; R$197.99 for seronegative patients; and R$ 3,260.93 for PD. Comparing to fund transfers from SUS, absorption costing yielded a difference of -269.7% for hepatitis B, +10.2% for hepatitis C, -2.0% for seronegative patients, and -29.8% for PD. For PH fund transfers, absorption costing for hepatitis B yielded a difference of -50.2%, +64.24% for hepatitis C, +56.27% for seronegative patients, and +48.26 for PD. Conclusion: The comparison of costs of dialysis therapy from the perspective of the service provider with fund transfers from SUS indicated that there are cost constraints in HD and PD.
引用
收藏
页码:204 / 214
页数:11
相关论文
empty
未找到相关数据